Medipharm welcomes U.S. reclassification of cannabis

Executive Summary

• Medipharm Labs welcomes the U.S. executive order to reclassify cannabis from Schedule 1 to Schedule 3 under the Controlled Substances Act, viewing it as a historic milestone that validates the company's pharmaceutical approach.
• The company highlights its strategic advantage in supplying U.S. clinical trials, citing its FDA site registration, Drug Establishment Licence (DEL), and proven experience shipping product for over 10 active trials, including the NIH-funded LiBBY study.
• Management anticipates that the rescheduling will accelerate cannabis-related medical research, remove barriers to federally compliant cannabis, and potentially unlock institutional investment from firms previously restricted by Schedule 1 trafficking clauses.

Key Details

• Regulatory Change: U.S. President Donald Trump issued an executive order to expedite the reclassification of cannabis from Schedule 1 to Schedule 3, recognizing its medical use and reducing research barriers.
• Company Credentials: Medipharm holds an FDA site registration, Drug Establishment Licence (DEL), cannabis drug licence, natural health product licence, and operates under Good Manufacturing Practices (GMP) and European Union GMP certification.
• Facility Status: The company operates the first FDA-audited purpose-built commercial cannabis facility in Canada and one of only a handful globally.
• Clinical Supply Track Record:
  • Supplied product for over 10 active clinical trials.
  • Notable example: The U.S. National Institutes of Health (NIH)-funded LiBBY study with the Keck School of Medicine of the University of Southern California.
  • This was the first Phase 2 clinical trial of its kind with an Active Pharmaceutical Ingredient (API) sourced from a Canadian licensed producer.
  • First shipment to the U.S. completed in 2023, with additional shipments in subsequent years leveraging DEA import permits.
• Market Impact: The rescheduling is expected to facilitate access to standardized medical-grade cannabis from registered suppliers and may pave the way for future federally sanctioned medical access programs similar to those in Canada, Australia, and Germany.
• Investment Potential: Reclassification may allow institutional investors previously restricted by Schedule 1 trafficking clauses to consider research-oriented cannabis companies, potentially increasing interest from pharmaceutical firms.

Notable Quotes

• David Pidduck, CEO: "This reclassification order is a historic milestone that validates Medipharm's pharmaceutical approach and one that we anticipate will strengthen our ability to expand U.S. clinical trial partnerships... We have already shipped product for U.S. trials, a capability that others may take years to achieve."
• U.S. President Donald Trump: "This reclassification order will make it far easier to conduct marijuana-related medical research, allowing us to study benefits, potential dangers and future treatments... It's going to have a tremendously positive impact."